Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Francisco Gimenez
AddedMar 31, 2024
UpdatedMay 31, 2026
Francisco Gimenez

Francisco Gimenez

Board Member, BigHat Biosciences

CrunchbaseLinkedIn

Francisco Gimenez's Career

BigHat Biosciences
BigHat Biosciences

San Mateo, CA, US

Board Member· Board
Appia Bio
Appia Bio

Los Angeles, CA, US

Board Member· Board
Unlearn.AI
Unlearn.AI

San Francisco, CA, US

Board Member· Board
Flywheel
Flywheel

Minneapolis, MN, US

Board Member· Board
BlueVoyant
BlueVoyant

New York City, NY, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Francisco Gimenez's Career

BigHat Biosciences
BigHat Biosciences
Series B$99.3M922019San Mateo, CA, US
Board Member· Board

Leadership at BigHat Biosciences

Vineeta AgarwalaVineeta AgarwalaBoard Member
Theresa TribbleTheresa TribbleCo-Founder
Denis DovganichDenis DovganichCo-Founder
Rob ChessRob ChessBoard Member
Peyton GreensidePeyton GreensideCo-Founder
Mark DePristoMark DePristoCo-Founder

Similar to BigHat Biosciences

Abterra BiosciencesAbterra BiosciencesSan Diego, CA, USAntibody Therapeuticsest. 2009Abterra BiosciencesSan Diego, CA, US · est. 2009

Abterra Bio: Pioneering next-gen antibody therapeutics with advanced technology and machine learning.

Seed · $4.4M9
Nabla BioNabla BioBoston, MA, USAntibody Designest. 2020Nabla BioBoston, MA, US · est. 2020

AI-driven design of therapeutic antibodies for complex diseases.

Seed · $11.4M9
AI ProteinsAI ProteinsBoston, MA, USProtein Therapeuticsest. 2021AI ProteinsBoston, MA, US · est. 2021

AI Proteins: A biotech firm specializing in the design and engineering of synthetic mini protein therapeutics.

Series B · $18.2M44
TenSixty BiosciencesTenSixty BiosciencesCambridge, MA, USTherapeuticsest. 2021TenSixty BiosciencesCambridge, MA, US · est. 2021

TenSixty BioSciences innovates small molecule therapeutics through high throughput experiments.

Series A · $7.2M50
Appia Bio
Appia Bio
Series A$52M462020Los Angeles, CA, US
Board Member· Board

Leadership at Appia Bio

David BaltimoreDavid BaltimoreBoard Member
Pin WangPin WangCo-Founder
JJ KangJJ KangCo-Founder
Lili YangLili YangCo-Founder
David MoskowitzDavid MoskowitzBoard Member
Unlearn.AI
Unlearn.AI
Series B$84.8M1752017San Francisco, CA, US
Board Member· Board

Leadership at Unlearn.AI

Jonathan WalshJonathan WalshCo-Founder
Charles FisherCharles FisherCo-Founder & CEO

Similar to Unlearn.AI

Deep 6 AIDeep 6 AIPasadena, CA, USPatient Recruitmentest. 2015Deep 6 AIPasadena, CA, US · est. 2015

Deep 6 AI: Accelerating patient matching for clinical trials using advanced AI technology.

Series A · $17.6M68
Avalon AIAvalon AILondon, Greater London, GBMedical Diagnosticsest. 2015Avalon AILondon, Greater London, GB · est. 2015

Avalon AI: Leveraging deep learning for early detection of brain diseases and improved clinical trials.

Seed · $120k75
l'école AIl'école AINew York City, NY, USSoftwareest. 2020l'école AINew York City, NY, US · est. 2020

NYC-based l'école AI, a computer vision platform, accelerates life sciences advancements using purposeful AI.

Seed · $3M4
Secure AI LabsSecure AI LabsCambridge, MA, USAI Models, Data Analysisest. 2017Secure AI LabsCambridge, MA, US · est. 2017

Secure AI Labs: Providing secure data analysis and AI model development, ensuring data-use control and privacy.

Seed · $8.1M38
Flywheel
Flywheel
Series D$105.3M1602012Minneapolis, MN, US
Board Member· Board

Leadership at Flywheel

Jim OlsonJim OlsonCEO
Brian WandellBrian WandellCo-Founder
Troy KopischkeTroy KopischkeBoard Member
Gunnar SchaeferGunnar SchaeferCo-Founder
BlueVoyant
BlueVoyant
Series E$665.5M6672017New York City, NY, US
Board Member· Board

Leadership at BlueVoyant

Brendan ConlonBrendan ConlonBoard Member
Abe PeledAbe PeledBoard Member
Steven MnuchinSteven MnuchinBoard Member
Tom GlocerTom GlocerBoard Member
James RosenthalJames RosenthalCEO
Guy SchoryGuy SchoryBoard Member

Francisco Gimenez's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Francisco Gimenez

Alex MooreAlex MooreCo-Founder · BackplaneMike VernalMike VernalGeneral Partner · Conviction PartnersJohn EltonJohn EltonBoard Member · Rapid RoboticsAjay AgarwalAjay AgarwalBoard Member · ClockwiseMichael DixonMichael DixonBoard Member · Clover HealthAlison Lange EngelAlison Lange EngelInvestor · Public